CD161-lectin-like transcript 1 axis beyond programmed cell death protein 1 in hepatitis B virus-associated hepatocellular carcinoma
World Journal of Gastrointestinal Oncology · 15.11.2026 · 18 (11)
DOI: 10.4251/wjgo.120101 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 15.11.2026. Verfasst von Hai Nguyen Ngoc Dang und 8 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Hepatitis B virus (HBV)-associated hepatocellular carcinoma develops in a chronically inflamed, tolerogenic liver microenvironment. In this setting, T-cell dysfunction limits the efficacy of programmed death-1 (PD-1) blockade. Emerging evidence from Liu et al published in the World Journal of Gastrointestinal Oncology suggests that CD161 may represent an additional inhibitory axis within exhausted CD8+ T cells that is not fully captured by the PD-1/ programmed death ligand-1 pathway. In their study, CD161+CD8+ T cells were enriched in tumor tissue, and CD161 expression persisted even as PD-1+ compartments contracted after PD-1 inhibition, suggesting that CD161-mediated restraint may remain active under therapeutic pressure. Mechanistically, sustained engagement of the CD161-lectin-like transcript 1 interaction may impair T-cell effector function and contribute to adaptive immune resistance in the HBV-infected liver. These findings highlight the importance of protein-level assessment of CD161 and parallel evaluation with PD-1 to accurately characterize immune inhibition. Key knowledge gaps include the cellular source of lectin-like transcript 1 within the tumor microenvironment, the influence of ongoing HBV virological activity on CD161+ T-cell subsets, and the identification of clinically meaningful progression endpoints. In this editorial, we place these findings in mechanistic and translational context, highlighting the potential role of the CD161-lectin-like transcript 1 axis as a complementary pathway of immune resistance beyond PD-1 blockade. Collectively, the current evidence supports a cautious, hypothesis-driven translational strategy to evaluate combined modulation of the CD161 and PD-1 axes in carefully selected patients with HBV-associated hepatocellular carcinoma.
Zitieren
APA
Dang, H. N. N., Tran, H. P., Vu, H. M., Nguyen, T. T., Thi, B. N. H., Ho, T. V., Christopher, A. A., Xuan, H. T., & Luong, T. V. (2026). CD161-lectin-like transcript 1 axis beyond programmed cell death protein 1 in hepatitis B virus-associated hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 18(11). https://doi.org/10.4251/wjgo.120101
Vancouver
Dang HNN, Tran HP, Vu HM, Nguyen TT, Thi BNH, Ho TV, et al. CD161-lectin-like transcript 1 axis beyond programmed cell death protein 1 in hepatitis B virus-associated hepatocellular carcinoma. World Journal of Gastrointestinal Oncology. 2026;18(11). doi:10.4251/wjgo.120101
BibTeX
@article{Dang2026,
author = {Dang, Hai Nguyen Ngoc and Tran, Hau Phuc and Vu, Hung Minh and Nguyen, Trung Tran and Thi, Bich Ngoc Hoang and Ho, Thanh Van and Christopher, Adegbesan Abiodun and Xuan, Hung Tran and Luong, Thang Viet},
title = {CD161-lectin-like transcript 1 axis beyond programmed cell death protein 1 in hepatitis B virus-associated hepatocellular carcinoma},
journal = {World Journal of Gastrointestinal Oncology},
year = {2026},
volume = {18},
number = {11},
doi = {10.4251/wjgo.120101}
}
EUVIMED